Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
ADARx Pharmaceuticals, Inc. · NCT07428499
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 3
- Target enrollment
- 90
- US sites recruiting
- 2
- Study start
- April 2, 2026
- Record last updated
- September 4, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
Being studied: ADX-324 Dose Level 1; ADX-324 Dose Level 2
Conditions: Hereditary Angioedema (HAE); Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; HAE
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Have a documented diagnosis of HAE (Type I or II)
- Completed Study ADX-324-301
- Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)
Exclusion Criteria
- A negative reaction to study drug in ADX-324-301
Recruiting US locations
ADARx Clinical Site
Las Vegas, NV 89128
ADARx Clinical Site
New York, NY 10029
Study contacts (from the official record)
- Lupe Gallegos · 877-232-7974 · info@adarx.com